Exhibit 12.1

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES

COMPUTATION OF RATIOS OF EARNINGS TO FIXED CHARGES AND

EARNINGS (LOSS) TO COMBINED FIXED CHARGES AND PREFERRED STOCK

DIVIDENDS

(In thousands, except ratios)

Our ratios of earnings to fixed charges and our ratios of earnings to combined fixed charges and tax-adjusted preferred stock dividends were as follows for the periods indicated in the table below.

	Nine Months Ended			Year ended December 31,
(Dollar amounts in thousands)	September 30, 2017			2016			2015		2014		2013			2012
Earnings:
Pre-tax income (loss) from continuing operations	$	(3,032	)	$	(1,335	)	$	1,246	$	3,744	$	(3,674	)	$	9,051
Fixed charges		204			299			241		219		256			225
Total earnings		(2,828	)		(1,036	)		1,487		3,963		(3,418	)		9,276
Fixed Charges:
Interest expense		71			106			74		67		103			72
Estimated interest portion of rent expense		133			193			167		152		153			153
Total fixed charges		204			299			241		219		256			225
Ratio of earnings to fixed charges (1)(2)		*			*			6.2		18.1		*			41.2
*Deficit (3)	$	3,032		$	1,335		$	—	$	—	$	3,674		$	—

(1) Our ratios of earnings to fixed charges and our ratios of earnings to combined fixed charges and tax-adjusted preferred stock dividends are calculated by dividing earnings by fixed charges and preference dividends, if any. For these purposes, earnings consist of pre-tax income (loss) from continuing operations plus fixed charges. Fixed charges consist of interest expense, which includes amortization of debt issuance costs, plus one-third (the proportion deemed to be representative of the interest factor) of rent expense.

(2) The Company did not have any preferred stock outstanding for any of the periods presented.

(3) Our earnings were inadequate to cover fixed charges for the nine months ended September 30, 2017 and the years ended December 31, 2016 and 2013.